

### REMARKS

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

By this Amendment, claim 1 is further amended to change "comprising" to "consisting essentially of." Thus, the method of claim 1 recites administering to the eye an aqueous eye drop **consisting essentially of** 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof and at least one organic amine selected from the group consisting of an amino acid, an alkanolamine, a piperazine and an aminoalkylsulfonic acid. As a result, the aqueous eye drop recited in claim 1 **excludes a liposome carrier**.

As discussed in the Amendment filed March 12, 2009, claim 1 would not have been obvious over Ogawa in view of Kato. Kato teaches liposome eye drops where taurine is encapsulated in a liposome of the liposome eye drops to enhance retentivity on the corneal surface for treating corneal injury and corneal damages. On the other hand, in the claimed invention, the effect of enhancing the treatment of inflammatory disease of the eye is achieved by mixing taurine with bromfenac, without the need for using a medium such as a liposome. That is, in the claimed invention, a liposome carrier is excluded.

In view of the foregoing amendments, and the amendments and remarks filed March 12, 2009, it is respectfully submitted that this application is in condition for allowance. Favorable reconsideration and prompt allowance of claims 1, 3, 5-7 and 9-11 are earnestly solicited.

Should the Examiner believe that anything further would be desirable in order to place the application in better condition for allowance, the Examiner is invited to contact the undersigned at the telephone number set forth below.

Respectfully submitted,

Shirou SAWA et al.

By: 

Andrew B. Freistein  
Registration No. 52,917  
Attorney for Applicants

WMC/ABF/vah  
Washington, D.C. 20005-1503  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
April 3, 2009

THE COMMISSIONER IS AUTHORIZED  
TO CHARGE ANY DEFICIENCY IN THE  
FEES FOR THIS PAPER TO DEPOSIT  
ACCOUNT NO. 23-0975